Проблемы вакцинопрофилактики глубоких микозов
Аннотация
В обзоре литературы представлены данные последних лет относительно стратегии получения и протективных свойств различных экспериментальных вакцин против оппортунистических и особо опасных глубоких микозов. Обсуждается роль Т-лимфоцитов Th1 и Th17 типов, взаимосвязи CD4+T- и СВ8+Т-клеток в иммунном ответе и сохранении иммунологической памяти после введения противогрибковой вакцины.
Ключевые слова
вакцина,
иммунопрофилактика,
иммунный ответ,
Т-клетки,
протективность,
vaccine,
immune prevention,
immune response,
T-cells,
protection
Об авторах
А. В. Липницкий
ФКУЗ «Волгоградский научно-исследовательский противочумный институт» Роспотребнадзора
Россия
Россия
Н. В. Половец
ФКУЗ «Волгоградский научно-исследовательский противочумный институт» Роспотребнадзора
Россия
Россия
В. А. Антонов
ФКУЗ «Волгоградский научно-исследовательский противочумный институт» Роспотребнадзора
Россия
Россия
Список литературы
1. Wuthrich M., Hung C.Y., Gern B.H., Pick-Jacobs J.C., Galles K.J., Filutowicz H.I. et al. A TCR transgenic mouse reactive with multiple systemic dimorphic fungi. J. Immunol. 2011; 187 (3): 1421 - 1431.
2. Hage C.A., Knox K.S., Wheat L.J. Endemic mycoses: overlooked causes of community acquired pneumonia. Resp. Med. 2012; 106: 769 - 776.
3. Cassone A., Casadevall A. Recent progress in vaccines against fungal diseases. Curr. Opin. Microbiol. 2012; 15 (4): 427 - 433.
4. Leibundgut-Landmann S., Wthrich M., Hohl T.M. Immunity to fungi. Cur. Opin. Immunol. 2012; 24:449 - 458.
5. Cutler J.E., Deepe G.S., Klein D. Advances in combating fungal diseases: vaccines on the threshold. Nat. Rev. Microbiol. 2007; 5:13 - 28.
6. Romani L. Immunity to fungal Infections. Nat Rev Immunol. 2011; 11: 275-288.
7. Blair J.E., Mayer A.P, Currier J., Files J.A., Wu Q. Coccidioidomycosis in elderly persons. Clin. Infect. Dis. 2008; 47:1513-1518.
8. Dierberg K.L., Marr K.A., Subramanian A., Nace H., Desai N., Locke J.E. et al. Donor-derived organ transplant transmission of coccidioidomycosis. Transpl. Infect. Dis. 2012; 14: 300 - 304.
9. Spellberg B. Vaccines for invasive fungal infections. F1000 Medicine Reports. 2011; 3:13.
10. Rappuoli R., Mandl C.W., Black S., De Gregorio E. Vaccines for the twenty-first century society. Nat. Rev. Immunol. 2011; 11: 865 - 872.
11. Moxon E.R., Siegrist C.A. The next decade of vaccines: societal and scientific challenges. Lancet. 2011; 378: 348 - 359.
12. Fidel PL. Jr., Cutler J.E. Prospects for development of a vaccine to prevent and control vaginal candidiasis. Curr. Infect. Dis. Rep. 2011; 13:102 - 1077.
13. Pietrella D., Rachini A., Torosantucci A., Chiani P., Brown A.J., Bistoni F. et al. A beta-glucan-conjugate vaccine and anti-b-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine. 2010; 28: 1717 - 1725.
14. Wang S.J. Candida vaccines development from point view of US patent application. Hum. Vaccin. 2011; 7 (11): 1165 - 1171.
15. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 2010; 36:1 - 53.
16. Baddley J.W., Winthrop K.L., Patkar N.M., Delzell E., Beukelman T., Xie F, et al. Geographic distribution of endemic fungal infections among older persons, United States. Emerg. Infect. Dis. 2011; 17: 1664 - 1669.
17. Datta K., Pirofski L.A. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res. 2006; 6: 525 - 536.
18. Capilla J., Clemons K.V., Liu M., Levine H.B., Stevens D.A. Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine. 2009; 27: 3662 -3668.
19. Ampel N.M. New perspectives on coccidioidomycosis. Proc. Am. Thorac. Soc. 2010; 7: 181 - 185.
20. Liu M., Capilla J., Johansen M.E., Alvarado D., Martinez M., Chen V. et al. Saccharomyces as a vaccine against systemic aspergillosis: ‘the friend of man’ a friend again? J. Med. Microbiol. 2011; 60: 1423 - 32.
21. Stevens D.A., Clemons K.V., Liu M. Developing a vaccine against aspergillosis. Med. Mycol. 2010; 49 (Suppl 1): S170 - S176.
22. Wthrich M., Krajaejun T., Shearn-Bochsler V., Bass C., Filutowicz H.I., Legendre A.M. et al. Tolerability, and immunogenicity of a recombinant, genetically engineered, live-attenuated vaccine against canine blastomycosis. Clin. Vaccine Immunol. May 2011; 18 (5): 783 - 789.
23. Wultrich M., Gern B., Hung C.Y., Ersland K., Rocco N., Pick-Jacobs J. et al. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 in mice. J. Clin. Invest. 2011; 121: 554 - 568.
24. Cole G.T., Hurtgen B.J., Hung C.-Y. Progress toward a human vaccine against coccidioidomycosis. Curr. Fungal Infect. Rep. 2012; 6 (4): 235 - 244.
25. Hurtgen B.J., Hung C.-Y., Ostroff G.R., Levitz S.M., Cole G.T. Construction and evaluation of a novel recombinant T cell epitope-based vaccine against coccidioidomycosis. Infect. Immun. 2012; 80 (11): 3960 - 3974.
26. Liu M., Clemons K.V., Johansen M.E., Martinez M., Chen V., Stevens D.A. Saccharomyces as a vaccine against systemic candidiasis. Immunol. Invest. 2012; 41 (8): 847 - 855.
27. Bromuro C., Romano M., Chiani P., Berti F., Tontini M., Proietti D. et al. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine. 2010; 28: 2615 - 2623.
28. Seubert A., Calabro S., Santini L., Galli B., Genovese A., Valentini S. et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Nat. Acad. Sci. US. 2011; 108: 11169 - 11174.
29. Torosantucci A., Chiani P., Bromuro C., De Bernardis F., Palma A.S., Liu Y. et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One. 2009; 4 (4): e5392.
30. Xin H., Cutler J.E. Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis. Clin. Vaccine Immunol. 2011; 18: 1656 - 1667.
31. Huang H., Ostroff G.R., Lee C.K., Specht C.A., Levitz S.M. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded b-glucan particles. MBio. 2010; 1: e00164-0.
32. Stuehler C., Khanna N., Bozza S., Zelante T., Moretti S., Kruhm M. et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood. 2011; 117: 5881 - 5891.
33. Crum-Cianflone N.F. Coccidioidomycosis in the U.S. military. Ann N Y Acad. Sci. 2007; 1111: 112 - 121.
34. Baptista Rosas R.C, Riquelme M. The epidemiology of coccidioidomycosis in Mexico. Rev. Iberoam. Micol. 2007; 24: 100 - 105.
35. Sifuentes-Osornio J., Corzo-Leon D.E., Ponce-de-Leon L.A. Epidemiology of invasive fungal infections in Latin America. Curr. Fungal Infect. Rep. 2012; 6: 23 - 34.
36. Spinello I.M., Munoz A., Johnson R.H. Pulmonary coccidioidomycosis. Semin. Respir. Crit. Care Med. 2008; 29: 166 - 173.
37. Johnson S.M., Kerekes K.M., Lunetta J.M., Pappagianis D. Characteristics of the protective subcellular coccidioidal T27K vaccine. Ann N Y Acad. Sci. 2007; 1111: 275 - 289.
38. Liu M., Clemons K.V., Bigos M., Medovarska I., Brummer E., Stevens D.A. Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine. 2011; 29: 1745 - 1753.
39. Wuthrich M., Deepe G.S., Klein B. Adaptive immunity to fungi. Annu Rev. Immunol. 2012; 30: 115 - 148.
40. Hung C-Y., Gonzalez A., W thrich M., Klein B.S., Cole G.T. Vaccine immunity to coccidioidomycosis occurs by early activation of three signal pathways of T helper cell response (Th1, Th2, and Th17) Infect Immun. 2011; 79: 4511 - 4522.
41. Hung C-Y., Hurtgen B.J., Bellecourt M., Sanderson S.D., Morgan E.L., Cole G.T. An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection. Vaccine. 2012; 30: 4681 - 4690.
42. Hurtgen B.J., Hung C-Y., Cole G.T. A human T-cell epitope-driven vaccine against San Joaquin Valley Fever [abstract]. 111th General Meeting, American Society for Microbiology; New Orleans, LA. 21 - 24 May 2011.
43. Tarcha E.J., Basrur V., Hung C-Y., Gardner M.J., Cole G.T. Multivalent recombinant protein vaccine against coccidioidomycosis. Infect. Immun. 2006; 74: 5802 - 5813.
44. Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int. J. Nanomed. 2012; 7: 2181 - 2195.
45. Nanjappa S.G., Heninger E., W thrich M., Sullivan T., Klein B. Protective antifungal memory CD8+ T cells are maintained in the absence of CD4+ T cell help and cognate antigen in mice. J. Clin. Invest. 2012; 122: 987 - 999.
46. Koneti A., Linke M.J., Brummer E., Stevens D. A. Evasion of innate immune responses: evidence for mannose binding lectin inhibition of tumor necrosis factor alpha production by macrophages in response to Blastomyces dermatitidis. Infect. Immun. 2008; 76 (3): 994 - 1002.
47. Deepe G.S. Tumor necrosis factor-alpha and host resistance to the pathogenic fungus, Histoplasma capsulatum. J. Investig. Dermatol. Symp. Proc. 2007; 12 (1): 34 - 37.
48. Nishikaku A.S., Molina R.F., Albe B.P., Cunha Cda. S., Scavone R., Pizzo C.R. et al. Immunolocalization of IFN-gamma in the lesions of resistant and susceptible mice to Paracoccidioides brasiliensis infection. FEMS Immunol. Med. Microbiol. 2011; 63: 281 - 288.
49. Braga C.J., Rittner G.M., Munoz Henao J.E., Teixeira A.F., Massis L.M., Sbrogio-Almeida M.E. et al. Paracoccidioides brasiliensis vaccine formulations based on the gp43-derived P10 sequence and the Salmonella enterica FliC flagellin. Infect. Immun. 2009; 77: 1700 - 1707.
50. Casadevall A., Pirofski L.A. Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe. 2012; 11: 447 - 456.
51. Diaz-Arevalo D., Bagramyan K., Hong T.B., Ito J.I., Kalkum M. CD4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine. Infect. Immun. 2011; 79: 266.
52. Fenoglio D., Poggi A., Catellani S., Battaglia F., Ferrera A., Seti M. et al. Vdelta1 T lymphocytes producing IFNg patients and IL-17 are expanded in HIV-infected and respond to Candida albicans. Blood. 2009; 113: 6611 - 6618.
53. Castellino F., Germain R.N. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev. Immunol. 2006; 24: 519 - 540.
54. Williams M.A., Tyznik A.J., Bevan M.J. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature. 2006; 441(7095): 890 - 893.
55. Fierer J., Waters C., Walls L. Both CD4+ and CD8+ T cells can mediate vaccine-induced protection against Coccidioides immitis infection in mice. J. Infect. Dis. 2006; 193: 1323 - 1331.
56. Bourgeois C., Majer O., Frohner I.E., Tierney L., Kuchler K. Fungal attacks on mammalian hosts: pathogen elimination requires sensing and tasting. Curr. Opin. Microbiol. 2010; 13 (4): 401 - 408.
Рецензия
Для цитирования:
Липницкий А.В., Половец Н.В., Антонов В.А. Проблемы вакцинопрофилактики глубоких микозов. Эпидемиология и Вакцинопрофилактика. 2016;15(3):66-71. https://doi.org/10.31631/2073-3046-2016-15-3-66-71
For citation:
Lipnitsky A.V., Polovete N.V., Antonov V.A. PROBLEMS OF VACCINAL PREVENTION OF DEEP MYCOSES. Epidemiology and Vaccinal Prevention. 2016;15(3):66-71. (In Russ.) https://doi.org/10.31631/2073-3046-2016-15-3-66-71
Просмотров: 418
Послать статью по эл. почте 